Search PubMed⌕ Search

Biomedical subjects

M Kornitzer

Publications and source records attributed to M Kornitzer.

131 records · Page 8Linked to original sources
PubMedDate not supplied

[Evaluation of technics used to define type 'A' pattern, in the Belgian Prevention Project of cardiovascular diseases (author's transl)].

In order to define the Rosenman and Friedman type A pattern three technics where used: the Bortner scale, the Jenkins Acitivity Survey (J.A.S.) and the interview. These are part of the base-line data recorded during the screening of a belgian male population aged 40 to 59 at entry of a controlled trial for the multifactorial prevention of cardiovascular diseases. The J.A.S. and the Bortner scale are evaluated in relation to the interview. Extremes of type A and B are less prevalent in our study compared to the Western Collaborative Group Study. Both the J.A.S. and the Bortner scale are very satisfactory in predicting type A and B pattern. The Bortner scale predicts the pattern in 78% of the subjects, by the method of weighted scores. The validation of this classification method, on a second sample, gives an accurate classification in 75% of the subjects. The J.A.S. predicts, the pattern in relation to the interview in 78% of the subjects; again the validation of the classification method, on a second sample, gives a correct classification in 70% of the subjects.

Behavior↗
PubMedDate not supplied

[Cardiovascular effects of replacement hormones].

The authors discuss the possibility of a consensus concerning hormone replacement therapy in relation with the risk of cardiovascular diseases in postmenopausal women anno 1995. Although there are not yet randomised clinical trials published concerning the effect of hormone replacement therapy, combined or not, on the incidence of coronary heart disease, the criteria for causal association seem to be indeed present. Relative risk of women on replacement therapy compared to those without such therapy is around 0.55; there is a gradient which expresses itself by an inverse correlation between the length of the hormonal replacement therapy and risk of coronary heart disease; this substitution therapy is most probably an independent protective factor; there are numerous possible pathogenetic mechanisms, the most important being likely a significant increase of HDL-cholesterol; animal experiments confirm the favourable effects of natural oestrogens on atherogenesis. Finally, a recent clinical trial seems to show that the favourable effects on the coronary risk profile are observed both with and without combined hormonal substitution therapy.

Aged↗